Policy Positions
0811 - Regulation of Dietary Supplement [HTML]
0813 - Medicare Prescription Drug Benefit [HTML]
0814 - Federal Review of Anticompetitive Practices by Drug Product Manufacturers [HTML]
0815 - Uniform State Laws and Regulations Regarding Pharmacy Technicians [HTML]
0716 - Regulation of Telepharmacy Services [HTML]
0719 - FDA Authority to Prohibit Reuse of Brand Names [HTML]
0722 - Pharmaceutical Product and Supply Chain Integrity [HTML]
0723 - Removal of Propoxyphene from the Market [HTML]
0602 - Minimum Effective Doses [HTML]
0612 - Streamlined Licensure Reciprocity [HTML]
0506 - Accessibility and Affordability of Pharmaceuticals [HTML]
0512 - Full Health Insurance Coverage [HTML]
0513 - Postmarketing Comparative Clinical Studies [HTML]
0514 - Premarketing Comparative Clinical Studies [HTML]
0515 - Postmarketing Safety Studies [HTML]
0516 - Mandatory Registry of Clinical Trials [HTML]
0518 - Funding, Expertise, and Oversight of State Boards of Pharmacy [HTML]
0519 - Approval of Generic Biologic Medications [HTML]
0411 - Compounding by Health Professionals [HTML]
0413 - Importation of Pharmaceuticals [HTML]
0319 - Drug Product Shortages [HTML]
0222 - Greater Access to Less Expensive Generic Drugs [HTML]
0012 - FDA’s Public Health Mission [HTML]
9902 - Compliance with Governmental Payment Policies [HTML]
9010 - Generic Pharmaceutical Testing [HTML]
All the ASHP policies listed above [PDF]
Statements
ASHP Statement: Criteria for an Intermediate Category of Drug Products [PDF]
ASHP Statement: Over-the-Counter Availability of Statins [PDF]
ASHP Statement: Principles for Including Medications and Pharmaceutical Care in Health Care Systems [PDF]